1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,240 | 4,545 | 16:06 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD ... | 1 | HKEx | ||
| 09.01. | Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C) | 418 | Business Wire | Die erweiterte Zusammenarbeit knüpft an die jüngsten gemeinsamen Entwicklungsanstrengungen von Acepodia und Biocytogen zur Evaluierung ausgewählter bispezifischer Antikörper- und Dual-Payload-ADC-Programme... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09.01. | Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C) | 265 | Business Wire | Expanded collaboration builds on Acepodia and Biocytogen's recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs
Biocytogen Pharmaceuticals (Beijing)... ► Artikel lesen | |
| 31.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 31.12.25 | BIOCYTOGEN-B (02315): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 24.12.25 | HSI Closes Up 44 Pts in Half-day Session as SMIC Leaps 3%+; BIOCYTOGEN-B Soars 20% | 5 | AASTOCKS | ||
| 24.12.25 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| 24.12.25 | BIOCYTOGEN-B Leapfrogs 20%+ after Being Added to Southbound Stock Connect | 3 | AASTOCKS | ||
| 24.12.25 | BIOCYTOGEN-B Added to List of Securities Eligible for Southbound Stock Connect, Effective Today | 3 | AASTOCKS | ||
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 472 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 525 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx | ||
| 10.12.25 | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 513 | Business Wire | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE STRATEGY COMMITTEE | 2 | HKEx | ||
| 10.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE REMUNERATION AND EVALUATION COMMITTEE | 2 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE AUDIT COMMITTEE | 1 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): ARTICLES OF ASSOCIATION | 3 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 09.12.25 | BIOCYTOGEN-B (02315): INSIDE INFORMATION COMPLETION OF THE ISSUE OF A SHARES; AND RESIGNATION OF EXECUTIVE DIRECTOR AND ELECTION OF EMPLOYEE DIRECTOR | 1 | HKEx |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,070 | +6,73 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| BIOFRONTERA | 2,460 | -3,53 % | Biofrontera sees Q4 2025 net sales of about $17M to $17.5M | ||
| CLINUVEL | 7,025 | -2,70 % | CLINUVEL PHARMACEUTICALS LIMITED: Managing Director Letter to Shareholders | ||
| EDITAS MEDICINE | 1,769 | +0,86 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 0,113 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,590 | -1,64 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,560 | +2,61 % | Zweite Chance 2026: +100% Kursgewinn damals - kommt jetzt die Wiederholung? | ||
| CLEAN HARBORS | 228,60 | +0,40 % | Why Clean Harbors Stock Triumphed on Tuesday | ||
| MESOBLAST | 1,450 | -5,23 % | Mesoblast Limited: FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy | NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,095 | +1,45 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| LIR LIFE SCIENCES | 1,235 | +2,49 % | LIR Life Sciences: Innovativer Gesundheitswert mit starkem Potenzial im auflebenden Sektor | Lüdenscheid (ots) - Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9) "LIR" oder das "Unternehmen", gibt den Abschluss einer Forschungs- und Entwicklungsvereinbarung mit "Neuland Laboratories... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,680 | +0,74 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INCLUSION OF GAVRETO (PRALSETINIB) IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST | ||
| PROTALIX BIOTHERAPEUTICS | 1,800 | +2,27 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 85,50 | -1,16 % | PALVELLA THERAPEUTICS, INC. - 8-K, Current Report | ||
| PURPLE BIOTECH | 0,633 | -2,62 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update | Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,655 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.